PPCB Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 15:23):

Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia...

Stats
Today's Volume	5.55M
Average Volume	3.85M
Market Cap	3.62B
EPS	$-0.0449 ( 2023-11-14 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.110
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-07-05	Zelinger Josef	Buy	15 000 000	Common Stock Purchase Warrant
2021-08-17	Kenyon Julian Norman	Buy	3 420 000	Common stock, par value $0.001
2021-08-17	Nathanielsz James Andrew	Buy	5 928 000	Common stock, par value $0.001
2021-08-17	Nathanielsz James Andrew	Buy	2 800 000	Common stock, par value $0.001
2021-08-17	Zelinger Josef	Sell	0	Common stock, par value $0.001

INSIDER POWER
100.00
Last 22 transactions
Buy: 280 061 820 \| Sell: 580 500

Volume Correlation

Long: -0.16 (neutral)

Short: -0.80 (strong negative)

Signal:(47.663) Neutral

Propanc Biopharma, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Propanc Biopharma, Inc. Correlation - Currency/Commodity

0.00
( neutral )

Propanc Biopharma, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-28 841.00 (0.00 %)
EPS:	$-1.530

Q4	2023
Revenue:	$0
Gross Profit:	$-6 597.00 (0.00 %)
EPS:	$-0.210

Q3	2023
Revenue:	$0
Gross Profit:	$-8 365.00 (0.00 %)
EPS:	$-0.420

Q2	2023
Revenue:	$0
Gross Profit:	$-7 506.00 (0.00 %)
EPS:	$-0.510

Financial Reports:

No articles found.

Propanc Biopharma, Inc.

Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.